Tools   Select Another Resource Report Type

http://dartmouth.eagle-i.net/i/0000012a-24fd-6cc0-d8a1-249280000000

Core facility that provides the following services: 7500 fast Q-PCR service, MALDI MS service, Agilent 2100 bioanalyzer service, NanoDrop 1000 service.

Proper citation: Dartmouth Shared Instruments Core Laboratory (RRID:SCR_006415) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012c-60c2-395c-c437-ff0b80000000

Core facility that provides the following services: Cell immortalization through retroviral or lentiviral vectors service, Microscopy training, User-based microscopy service.

Proper citation: BWH Cell Culture and Microscopy Core (RRID:SCR_005562) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00059202

Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway.

Proper citation: High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) Copy   

•   Source: SciCrunch Registry

http://www.unsw.edu.au/

Proper citation: University of New South Wales; New South Wales; Australia (RRID:SCR_006094) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/ct2/show/study/NCT00248638

Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity.

Proper citation: Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) Copy   

•   Source: SciCrunch Registry

http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx

Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk

Proper citation: Diabetes Control and Complications Trial (RRID:SCR_006805) Copy   

•   Source: SciCrunch Registry

http://www.mcw.edu/EPRCenter.htm

Biomedical technology research center focusing on technological innovation and application of new techniques to biological problems. The main areas of research are free radicals, spin labeling, metal complexes, and metallo proteins. Spectrometers are available for S-, X-, L-, Q- , and W-band EPR, many with ENDOR, ELDOR, saturation-transfer, saturation-recovery, and multiquantum capabilities. * Development of multiquantum Q- and W-band spectrometers, including multiquantum ELDOR, development of time-locked sub-sampling (TLSS) for broadband detection of periodically modulated signals * Development of loop-gap resonators using finite element modeling of Maxwell''s equations * Application of multifrequency (1 to 100 GHz) electron paramagnetic resonance (EPR) to characterize paramagnetic centers * Study of relaxation processes using multifrequency pulse saturation recovery * Use of nitroxide radical spin labels to measure translational and rotational diffusion in biological systems, site-directed spin labeling (SDSL), and use of EPR for the detection of nitric oxide and oxy radicals

Proper citation: National Biomedical Electron Paramagnetic Resonance Center (RRID:SCR_006601) Copy   

•   Source: SciCrunch Registry

http://www.pathxl.com/pathxl-research/pathxl-tma

Tissue microarray (TMA) Software used for Biomarker Discovery that allows TMA experiments to be performed anytime, anywhere, reducing administrative costs and time. It is designed to support TMA scoring workflow and allows configuration of experiments in minutes. Access and view clinical metadata, the TMA core, scoring criteria and the TMA map all on a single interface.

Proper citation: PathXL TMA (RRID:SCR_005596) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00271999

Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia

Proper citation: Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) Copy   

•   Source: SciCrunch Registry

http://sccn.ucsd.edu/wiki/BCILAB

Open Source MATLAB toolbox and EEGLAB plugin for the design, prototyping, testing, experimentation with, and evaluation of Brain-Computer Interfaces (BCIs), and other systems in the same computational framework. It facilitates the design and development of new methods for cognitive state estimation and their use in both offline data analysis and real-time applications. BCILAB includes an easily extensible collection of currently over 100 methods from the literature (covering signal processing, machine learning and BCI-specific methods). Aside from supporting advanced BCI research, a special aim of BCILAB is to facilitate the adoption of machine learning and advanced statistical modeling for functional neuroimaging purposes in tandem with the EEGLAB platform. The toolbox offers multiple different interfaces which link to the same backend functionality, including a GUI, scripting support (MATLAB-based), APIs for real-time processing, and a variety of extension component interfaces. MATLAB programming is not strictly necessary, as most BCILAB features can be accessed from the GUI, although it is required for batch scripting and custom extensions. The strength of MATLAB-based software lies in its resources for leading-edge scientific computing, as well as in the good support for rapid prototyping, but BCI systems developed in it can be used for real-time out-of-lab experimentation, and can in principle be deployed without the need for a MATLAB license. However, due to the complexity and overhead of the MATLAB environment, the system is best used as a research platform, and not as a product development environment -- end-user software is ideally re-implemented in a compiled language, after a suitable approach has been identified and extensively tested. The process of identifying and testing an approach involves more than just computation, but also data exploration and investigation - an area which is helped by the deep integration with the EEGLAB platform. In the future, this integration will be further strengthened, bringing rich statistical learning and signal processing into routine EEG analysis workflows. The toolbox has been developed by C. Kothe at the Swartz Center, inspired by the preceding PhyPA BCI toolbox created by C. Kothe and T. Zander at the Chair for Human-Machine Systems, Berlin Institute of Technology.

Proper citation: BCILAB (RRID:SCR_007013) Copy   

•   Source: SciCrunch Registry

http://uwaterloo.ca/

Proper citation: University of Waterloo; Ontario; Canada (RRID:SCR_006166) Copy   

•   Source: SciCrunch Registry

http://www.utexas.edu

A major university

Proper citation: University of Texas at Austin; Texas; USA (RRID:SCR_005900) Copy   

•   Source: SciCrunch Registry

https://github.com/Illumina/strelka/

Software for somatic single nucleotide variant (SNV) and small indel detection from sequencing data of matched tumor-normal samples. Strelka2 germline and somatic small variant caller.

Proper citation: Strelka2 (RRID:SCR_005109) Copy   

•   Source: SciCrunch Registry

http://www.uottawa.ca/

University of Ottawa often referred to as uOttawa or U of O, is a bilingual public research university in Ottawa, Ontario, Canada.

Proper citation: University of Ottawa; Ontario; Canada (RRID:SCR_006319) Copy   

•   Source: SciCrunch Registry

http://www.uni-wuerzburg.de/en/

Proper citation: University of Wurzburg; Bavaria; Germany (RRID:SCR_007008) Copy   

•   Source: SciCrunch Registry

http://www.usc.es/en/index.html

Proper citation: University of Santiago de Compostela; Santiago de Compostela; Spain (RRID:SCR_007888) Copy   

•   Source: SciCrunch Registry

http://www.remedyinformatics.com/

Software to harmonize the data that you have in different Excel files, databases, repositories, biospecimen applications, etc. and maps it to one common registry. Remedy Informatics' platform aggregates data from multiple sources, harmonizes the data via Ontology, and provides data visualization and pattern recognition and querying tools.

Proper citation: Registry Builder Data Harmonization and Aggregation Tool (RRID:SCR_006559) Copy   

•   Source: SciCrunch Registry

http://www.ens.fr/

Proper citation: University of Paris; Paris; France (RRID:SCR_006398) Copy   

•   Source: SciCrunch Registry

http://www.dnabaser.com/download/chromatogram-explorer/

A Windows Explorer clone dedicated to DNA sequence analysis and manipulation. View, edit, and convert chromatograms. Trim low quality ends automatically. The Lite version of Chromatogram Explorer is freeware.

Proper citation: DNA Chromatogram Explorer (RRID:SCR_005585) Copy   

•   Source: SciCrunch Registry

http://www.medschool.pitt.edu/

Proper citation: University of Pittsburgh School of Medicine; Pennsylvania; USA (RRID:SCR_006674) Copy   

•   Source: SciCrunch Registry